Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors), PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Triple Negative Breast Cancer | Preclinical | - | 01 Jan 2026 |





